Theoretically more promising is the IL-6 block [256], Ziltivekimab, a monoclonal antibody targeting the IL-6 ligand that significantly reduces inflammation and thrombosis biomarkers linked to atherosclerosis. The gene discussed is IL6; the disease is atherosclerosis.